Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

Steps to better asthma care A guide for primary care.
Use of Medications in Asthma Cyril Grum, M.D. Department of Internal Medicine *Based on the University of Michigan Guidelines for Clinic Care and the National.
WHEEZING AND ASTHMA Effective management of continuing symptoms Dr Duncan Keeley.
British Guideline on the Management of Asthma. BTS/SIGN Guidance May 2008 (revised July 2009)
1 Paediatric asthma The British Thoracic Society Scottish Intercollegiate Guidelines Network Thorax 2003; 58 (Suppl I): i1-i92.
Childhood asthma Rod Addis, Vanessa Kerai. Overview Prevalence Prevalence Aetiology Aetiology Pathophysiology Pathophysiology Clinical features Clinical.
Paediatric asthma Thorax 2003; 58 (Suppl I): i1-i92.
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.
G IN A lobal itiative for sthma lobal itiative for sthma.
Asthma Diagnosis Prescribing Acute Management Tracey Bradshaw Respiratory Consultant RIE.
Asthma What is Asthma ? V1.0 1997 Merck & ..
Inhaler technique is it important?. Compton et al (2006) Review of evidence from 6 European countries ( Spain, Italy, France, Germany, Netherlands, UK)
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
British Guideline on the Management of Asthma. Aims Review of current SIGN/BTS guidelines –Diagnosing Asthma –Stepwise management of Asthma –Managing.
Component 3: Pharmacologic Therapy n Asthma is a chronic inflammatory disorder of the airways. n A key principle of therapy is regulation of chronic airway.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 76 Drugs for Asthma.
Asthma is a chronic inflammatory disease of the airways, characterized by coughing, wheezing, chest tightness, and difficult breathing.
Paediatric Asthma Maria Tracey Paediatric Pharmacist Jane Davis Paediatric Clinical Nurse Specialist CF/Respiratory Royal Alexandra Hospital Paisley.
Impact of Montelukast on Symptoms of Mild-to-Moderate Persistent Asthma and Exercise-Induced Asthma: The ASTHMA Survey The ASTHMA* survey was supported.
Karen Homan NHS Bedfordshire
Classification and guideline treatment
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Asthma in children Dr Gulamabbas Khakoo BMBCh, FRCPCH
MANAGEMENT OF ASTHMA 6 Penaflor, Dominic Quinto, Milraam Ramos,Josefa Victoria Sicat, Gracie Suaco, David Tio- Cuizon, Jeremiah Valenzuela, Virginia Lou.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
Acute and chronic management of childhood asthma
CHRONIC ASTHMA GUIDELINES IN ADOLESCENTS & ADULTS 2007 Bushra A. Hadi Asthma Guidelines Implementation Project.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
Component 4 Medications.
Classification of Chronic Asthma Severity on Treatment Domains/EstimatesIntermittentPersistent Mild to Moderate Severe** Daytime symptoms MonthlyWeeklyDaily.
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
An Update in Pediatric Asthma DR.NUFOUD AL- SHAMMARI CONSULTANT PEDIATRIC PULMONOLOGIST CHAIRPERSON OF MUBARK AL-KABEER HOSPITAL KUWAIT.
Asthma Guidelines, Diagnosis and Management Alison Hughes Respiratory Specialist Nurse Solent NHS Trust.
Definition of asthma Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory.
Wendy Pigg Practice support Pharmacist/Independent Prescriber
Overview of Changes to the NAEP Asthma Guidelines Breathe California’s Clinical Asthma Collaborative Susan M. Pollart, MD, MS University of Virginia Family.
Pharmacologic Treatment Of Asthma 1 د. ميريانا البيضة.
내과 R2 이지훈 N Engl J Med Sep 8.
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Linda Rogers and Joan Reibman Curr Opin Pulm Med. (2012) January Vol. 18 Stepping down asthma treatment: how and when Journal club R4. Yoo,
Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Dr Mazen Qusaibaty MD, DIS / Head Pulmonary and Internist Department Ibnalnafisse Hospital Ministry of Syrian health – Dr Mazen.
PICH Childhood Asthma project Bina Chauhan Locum GP 4/5/16.
Jessica Case study.
Respiratory disorders
Therapeutics 2 Tutoring: Asthma
Global Initiative for Asthma (GINA) Teaching slide set 2017 update
Research where it is most needed National Respiratory Strategy
Monitoring asthma in primary care
Asthma/ Wheeze and children
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control  Barbara P. Yawn, MD, MSc  Mayo Clinic Proceedings 
Asthma Annual Reviews Hetal Dhruve Presented by Anh Vu
Asthma diagnosis and treatment: Filling in the information gaps
The Modern Management of Asthma: Getting it right Part 2
12 months before treatment 12 months after treatment
Respiratory disorders
Evidence-Based Asthma Guidelines
Childhood Asthma : Lessons still to be learnt
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
G IN A lobal itiative for sthma.
The efficacy and safety of omalizumab in pediatric allergic asthma
Prescribing Update - Respiratory July 2019
Asthma Education for Families and HCPs
Introduction Project At Crown Street Surgery:
Presentation transcript:

Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)

Fine Tuning Asthma control means: - Minimal symptoms during day and night -Minimal need for reliever medication -No exacerbations -No limitation of physical activity -Normal lung function (FEV1 and/or PEF >80% predicted or best) Asthma Management

Fine Tuning Before initiating a new drug therapy: - Check compliance with existing therapies -Check inhaler technique ( Reconsider inhaler delivery system) -Eliminate trigger factors Asthma Management

Fine Tuning Asthma Management Step-wise approach Adults 5 steps Children 5-12 Years 5 steps Children < 5 Years 4 steps

Asthma Management Step 1:Mild intermittent asthma Step 2:Introduction of regular preventer therapy Step 3:Add-on therapy Step 4:Poor control on moderate dose of inhaled steroids + Add on Step 5:Use of oral steroids Adults

Preventers: Inhaled corticosteroids (ICS) 1 st Choice Moderate Dose: Adults  mcg/day Children  mcg/day BDP= Becotide (Beclomethasone Dipropionate) = Pulmicort (Budesonide) Flexotide (Fluticasone)½ dose of BDP High Dose ICSAdults  2000 mcg/day Children  800 mcg/day Asthma Management

Add-On therapy 1 st Choice LABA Adults/ Children 5-12 years LABA should not be used without ICS Others 2 nd choice: LTRAs 3 rd choice: SR Theophylline 4rth choice: Oral LABA ( SR Be agonists tab) S.E Asthma Management

Step 1: Mild intermittent asthma -Prescribe inhaled short-acting  2 agonist as short term reliever therapy for all patients with symptomatic asthma -Review asthma management in patients with high usage of inhaled short acting  2 agonists Asthma Management

Step 2: Introduction of regular preventer therapy when?  Recent exacerbations  Nocturnal asthma  Impaired lung function  Using inhaled B2 agonist >once a day  Using inhaled B2 agonists > 3 times per week Asthma Management

Step 2: Introduction of regular preventer therapy  Inhaled steroids are the 1 st line preventers  Give inhaled steroids initially twice daily  If good control, once a day inhaled steroids at the same total daily dose Asthma Management

Step 2: Introduction of regular preventer therapy  Start patients at inhaled steroid dose appropriate to disease severity  Adults: 400 mcg per day  Children 5-12 years: 200 mcg per day  Children under 5 years: higher doses may be required to ensure consistent drug delivery  Use lowest dose at which effective control is maintained  Monitor children’s height on a regular basis Asthma Management

Poor control  Still symptoms or  Sleep disturbance or  Restriction of activity  Despite use of regular inhaled steroid + PRN bronchodilator Asthma Management

Poor control – Therapeutic options 1) check compliance 2) check inhaler technique 3) Add LABA 1 st Choice: Adults/ children 5-12 (in children <5 years LTRAs preferred) 4) Suboptimal or no response : →  dose of inhaled steroid (800 mcg adult, 400 mcg children via spacer device 5) Poor control persist→ consider additional therapy: LTRAs, SR Theophylline or SR oral B 2 agonist + Increase Inhaled steroid to 2000 mcg/day 6) Oral steroids Asthma Management

Step 3: Add-on therapy Inadequate control on low dose inhaled steroids Asthma Management

Step 3: Add-on therapy Inadequate control on low dose inhaled steroids Add inhaled long-acting ß 2 agonist (LABA) Asthma Management

Step 3: Add-on therapy Inadequate control on low dose inhaled steroids Assess control of asthma Add inhaled long-acting ß 2 agonist (LABA) Asthma Management

Step 3: Add-on therapy Good response to LABA: Continue LABA Continue LABA Inadequate control on low dose inhaled steroids Assess control of asthma Add inhaled long-acting ß 2 agonist (LABA) Benefit from LABA but control still inadequate: Continue LABA Continue LABA Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) No response to LABA: Stop LABA Stop LABA Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Asthma Management

Good response to LABA: Continue LABA Inadequate control on low dose inhaled steroids Add inhaled long-acting ß 2 agonist (LABA) Benefit from LABA but control still inadequate: Continue LABA Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Control still inadequate: Trial of other add-on therapy, e.g. leukotriene receptor antagonist or theophylline Trial of other add-on therapy, e.g. leukotriene receptor antagonist or theophylline No response to LABA: Stop LABA Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Assess control of asthma Asthma Management Step 3

Inadequate control on low dose inhaled steroids If control still inadequate go to Step 4 Add inhaled long-acting ß 2 agonist (LABA) Benefit from LABA but control still inadequate: Continue LABA and Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Control still inadequate: Trial of other add-on therapy, e.g. leukotriene receptor antagonist or theophylline If control still inadequate go to Step 4 Assess control of asthma No response to LABA: Stop LABA Increase inhaled steroid dose to 800mcg/day (adults) and 400mcg/day (children 5-12 years) Good response to LABA: Continue LABA Asthma Management Step 3

Step 4: poor control on moderate dose of inhaled steroids + Add on   inhaled steroids to 2000 mcg/day (adult) or 800 mcg/day (children)  LTRAs OR SR Theophylline OR Oral SR B2 agonist  Consider referring to specialist care before proceeding to step 5 Asthma Management

Step 5: Use of oral steroids  Maintenance course (long term)  Plus drugs in step 4 Asthma Management

Step 1: Mild intermittent asthma Inhaled short acting ß 2 agonist as required Stepwise management of asthma in adults Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92

Stepwise management of asthma in adults Step 2: Regular preventer therapy Add inhaled steroid mcg/day * 400mcg is an appropriate starting dose for many patients Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent

Stepwise management of asthma in adults Step 3: Add-on therapys 1. Add inhaled long-acting ß 2 agonist (LABA) 2. Assess control of asthma: good response to LABA – continue LABA good response to LABA – continue LABA benefit from LABA but control still inadequate – continue LABA and increase inhaled steroid dose to 800mcg/day * (if not already on this dose) benefit from LABA but control still inadequate – continue LABA and increase inhaled steroid dose to 800mcg/day * (if not already on this dose) no response to LABA – stop LABA and increase inhaled steroid to 800mcg/day *. If control still inadequate, institute trial of other therapies (e.g. leukotriene receptor antagonist or SR theophylline) no response to LABA – stop LABA and increase inhaled steroid to 800mcg/day *. If control still inadequate, institute trial of other therapies (e.g. leukotriene receptor antagonist or SR theophylline) Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Step 2: Regular preventer therapy Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent

Stepwise management of asthma in adults Step 4: Persistent poor control Consider trials of: increasing inhaled steroid up to 2000mcg/day * increasing inhaled steroid up to 2000mcg/day * addition of fourth drug (e.g. leukotriene receptor antagonist, SR theophylline, ß 2 agonist tablet) addition of fourth drug (e.g. leukotriene receptor antagonist, SR theophylline, ß 2 agonist tablet) Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Step 3: Add-on therapy Step 2: Regular preventer therapy Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent

Stepwise management of asthma in adults Step 5: Continuous or frequent use of oral steroids Use daily steroid tablet in lowest dose providing adequate control Maintain high dose inhaled steroid at 2000mcg/day * Consider other treatments to minimise the use of steroid tablets Refer patient for specialist care Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Step 3: Add-on therapy Step 2: Regular preventer therapy Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent Step 4: Persistent poor control

Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Stepwise management of asthma in adults Step 1: Mild intermittent asthma Step 5: Continuous or frequent use of oral steroids Step 4: Persistent poor control Step 3: Add-on therapy Step 2: Regular preventer therapy

Stepwise management of asthma in children aged 5-12 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Inhaled short acting ß 2 agonist as required

Stepwise management of asthma in children aged 5-12 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 2: Regular preventer therapy Add inhaled steroid mcg/day * (other preventer drug if inhaled steroid cannot be used) 200mcg is an appropriate starting dose for many patients Step 1: Mild intermittent asthma Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent

Stepwise management of asthma in children aged 5-12 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 3: Add-on therapy 1. Add inhaled long-acting ß 2 agonist (LABA) 2. Assess control of asthma: good response to LABA – continue LABA. good response to LABA – continue LABA. benefit from LABA but control still inadequate – continue LABA and increase inhaled steroid dose to 400mcg/day * (if not already on this dose). benefit from LABA but control still inadequate – continue LABA and increase inhaled steroid dose to 400mcg/day * (if not already on this dose). no response to LABA – stop LABA and increase inhaled steroid to 400mcg/day *. If control still inadequate, institute trial of other therapies (e.g. leukotriene receptor antagonist or SR theophylline). no response to LABA – stop LABA and increase inhaled steroid to 400mcg/day *. If control still inadequate, institute trial of other therapies (e.g. leukotriene receptor antagonist or SR theophylline). Step 1: Mild intermittent asthma Step 2: Regular preventer therapy Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent

Stepwise management of asthma in children aged 5-12 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 4: Persistent poor control Increase inhaled steroid up to 800mcg/day * Step 1: Mild intermittent asthma Step 3: Add-on therapy Step 2: Regular preventer therapy Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent

Stepwise management of asthma in children aged 5-12 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 5: Continuous or frequent use of oral steroids Use daily steroid tablet in lowest dose providing adequate control Maintain high dose inhaled steroid at 800mcg/day * Refer patient to respiratory paediatrician Step 1: Mild intermittent asthma Step 3: Add-on therapy Step 2: Regular preventer therapy Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent Step 4: Persistent poor control

Stepwise management of asthma in children aged 5-12 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Step 5: Continuous or frequent use of oral steroids Step 4: Persistent poor control Step 3: Add-on therapy Step 2: Regular preventer therapy

Stepwise management of asthma in children under 5 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Inhaled short acting ß 2 agonist as required

Stepwise management of asthma in children under 5 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 2: Regular preventer therapy Add inhaled steroid mcg/day * † (leukotriene receptor antagonist if inhaled steroid cannot be used) Step 1: Mild intermittent asthma Start at dose of inhaled steroid appropriate to severity of disease. * BDP or equivalent † Higher nominal doses may be required if drug delivery is difficult required if drug delivery is difficult

Stepwise management of asthma in children under 5 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 3: Add-on therapy In children aged 2-5 years consider addition of leukotriene receptor antagonist In children under 2 years consider proceeding to step 4 Step 1: Mild intermittent asthma Step 2: Regular preventer therapy

Step 3: Add-on therapy Step 2: Regular preventer therapy Stepwise management of asthma in children under 5 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 4: Persistent poor control Refer to respiratory paediatrician Step 1: Mild intermittent asthma

Stepwise management of asthma in children under 5 years Pharmacological management. Thorax 2003; 58 (Suppl I): i1-i92 Step 1: Mild intermittent asthma Step 4: Persistent poor control Step 3: Add-on therapy Step 2: Regular preventer therapy

Stepping down  Important to review patients regularly as they step down  Patients should be maintained at the lowest possible dose of inhaled steroids  Reductions should be considered every 3 months  Reducing the dose by 25-50% each time Asthma Management

Exercise Induced Asthma  Often indicates poorly controlled asthma  For patients taking inhaled steroids add:  LABA  LTRAs  Cromones  Oral B2 agonist  Theophylline  Inhaled short acting B2 agonists immediately before exercise Asthma Management

Seasonal asthma  Start prophylactic steroid therapy before season begin Asthma Management

Exacerbations Occasional attacks between period of good control which can predicted by warning signs Asthma Management

Exacerbations warning signs  Increase symptoms  Sleep disturbance  Fall in exercise tolerance  Increase need for bronchodilator  Decrease effectiveness of bronchodilator  falling PEF  wide variations in PEF  inability to achieve optimum PEF after B agonist Asthma Management

Exacerbations Asthma Management

Management of exacerbations  Provide emergency supply oral steroids (Rescue Course) → to take at the 1st warning sign  seek medical help  written action plan  Time spent with patient for “What to do and When” will help prevent acute attack Asthma Management

Rescue course oral steroid  20 mg Children 2-5 years  mg Children >5 y ↨ 3 days *The dose should be repeated if child vomited  mg Adult: 5 days or until recovery Asthma Management

When do you stop medication? Asthma Management

When do you stop medication?  Adult with stable asthma is possible to reduce inhaled steroids without losing control  On average step down gradually by 25% (Hawkins et al 2003)  Keep patient under regular review even when well controlled Asthma Management

How do you know if a child is growing out of well controlled asthma if the prophylactic therapy is never reduced for a trial period?  Often patients stops medications themselves when they are better  Reducing treatment gradually to the minimum dose possible before medication is stopped  No exacerbations  No symptoms  No B 2 use  If symptoms recur medications should be restarted. Asthma Management